Roche Inks ‘The Largest Obesity Deal To Date’ With Zealand Pharma At $5.3 Billion ALLISON GATLIN Investor’s Business Daily

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

The post Roche Inks ‘The Largest Obesity Deal To Date’ With Zealand Pharma At $5.3 Billion appeared first on Investor’s Business Daily.

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

The post Roche Inks ‘The Largest Obesity Deal To Date’ With Zealand Pharma At $5.3 Billion appeared first on Investor’s Business Daily.

 Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
The post Roche Inks ‘The Largest Obesity Deal To Date’ With Zealand Pharma At $5.3 Billion appeared first on Investor’s Business Daily.   Read MoreTechnology, All News And Stock Ideas, Biotech And Pharma Stock News, Weight-Loss Drugs Investor’s Business Daily